Should I Buy MLAB? MLAB 2026 Analysis

Should You Buy Mesa Laboratories Inc (MLAB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

93.270

1 Day change

2.27%

52 Week Range

155.120

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price is extended/overbought and sitting just below a key resistance zone.
Fundamental/news tone is improving (recent earnings beat, margin expansion), but near-term upside looks more limited versus immediate technical risk.
Best stance here is HOLD/avoid chasing; a pullback toward support would offer a materially better entry than buying at ~92 with RSI stretched.

Technical Analysis

Trend: Bullish (SMA_5 > SMA_20 > SMA_200), indicating a strong uptrend across short/medium/long horizons.
Momentum: MACD histogram +0.685 and expanding, confirming bullish momentum is still building.
Overbought risk: RSI_6 at 78.95 (extended); probability stats also skew slightly negative for next day/week.
Key levels: Pivot 86.33 (important support/mean-reversion area). Near resistance R1 94.22; a breakout above ~94.2 would be constructive, but failure here increases pullback odds.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Earnings/event catalyst: Q4 GAAP EPS $0.65 beat by $0.37; revenue $65.13M beat and +3.6% YoY.
- Profitability trend: Adjusted operating income +17.6% with margin expansion despite FX headwinds.
- Underlying demand signal: Ex-CG China, non-GAAP organic revenue growth was 5.7% (stronger global performance).
- Street tone improving: multiple price-target raises recently, suggesting confidence is rebuilding.

Neutral/Negative Catalysts

- Technical positioning: RSI is stretched (near-term pullback risk), and price is close to resistance (~94.22).
- Short-term pattern stats: Similar-pattern projection implies mild weakness next day/week (though positive over the next month).
- Reported profitability volatility: Net income/EPS show large YoY declines in the provided snapshot (even as margins improved), which can cap enthusiasm if investors focus on GAAP/reported swings.
- Sentiment/trading flows: Hedge funds and insiders are neutral (no strong “smart money” confirmation).

Financial Performance

Latest quarter (as provided: 2026/Q3): Revenue $65.13M, +3.64% YoY (steady growth).
Margin: Gross margin 64.18%, +1.45 YoY (positive operational efficiency trend).
Bottom line: Net income $3.63M and EPS $0.65 are shown as sharply down YoY in the snapshot, indicating reported earnings volatility even while operations/margins improved.
Overall read: Top-line growth and margins are moving the right way; reported net income/EPS trend in the snapshot is the key mixed factor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: Price targets have been raised into early 2026.
Wells Fargo (2026-02-04): Equal Weight; PT raised to $94 from $83 (now only slightly above current ~92), citing revenue/EBITDA beat, margin expansion, leverage down, and more shareholder-friendly actions.
Jefferies (2025-11-07): Buy; PT raised to $115 from $110, expecting re-rating as stability/credibility returns.
Wall Street pros: Improving fundamentals (margins, de-levering) and potential re-rating case.
Wall Street cons: A meaningful portion of the Street view (Wells) is still neutral with a PT close to today’s price, implying limited immediate upside and a need for continued execution.

2 Analyst Rating

Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 99 USD with a low forecast of 83 USD and a high forecast of 115 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 91.200

Low

Averages

High

115

Current: 91.200

Low

Averages

High

115

Wells Fargo

Equal Weight

maintain

$83 -> $94

AI Analysis

2026-02-04

New

Reason

Wells Fargo

Price Target

$83 -> $94

AI Analysis

2026-02-04

New

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Mesa Labs to $94 from $83 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat on Q3 revenue and adjusted EBITDA, with strong margin expansion despite foreign-exchange headwinds. With numbers moving up, leverage down and management taking more shareholder-friendly steps, there's more room for valuation to re-rate, in Wells' view.

Wells Fargo

Equal Weight

maintain

$75 -> $83

2025-12-15

Reason

Wells Fargo

Price Target

$75 -> $83

2025-12-15

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Mesa Labs to $83 from $75 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MLAB

Unlock Now

MLAB Should I Buy

MLAB Should I Buy

Should You Buy Mesa Laboratories Inc (MLAB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch